Mechanisms of Weight Loss With SGLT2 Inhibition

Trial Profile

Mechanisms of Weight Loss With SGLT2 Inhibition

Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Overweight; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
    • 18 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top